A Phase 1b Study Evaluating the Safety and Pharmacokinetics of Venetoclax as a Single-Agent and in Combination With Azacitidine in Subjects With Relapsed/Refractory Myelodysplastic Syndromes
Latest Information Update: 11 May 2023
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Venetoclax (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 12 Apr 2023 Status changed from active, no longer recruiting to completed.
- 08 Dec 2022 Planned End Date changed from 31 Jan 2023 to 30 Jun 2023.
- 08 Dec 2022 Planned primary completion date changed from 31 Jan 2023 to 30 Jun 2023.